<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200486</url>
  </required_header>
  <id_info>
    <org_study_id>02-05-127E</org_study_id>
    <secondary_id>NIH-R21-CA104402</secondary_id>
    <secondary_id>6R21DE023941-03</secondary_id>
    <nct_id>NCT00200486</nct_id>
  </id_info>
  <brief_title>Molecular and Genomic Profiling of Head and Neck Tumors</brief_title>
  <official_title>Molecular and Genomic Profiling of Head and Neck Tumors to Explore Biomarkers Associated With Prognosis and Response to Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the genetic profile of head and neck tumors and their&#xD;
      relationship to treatment response and outcome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research by our group using genetic microarray analysis of HNSCC and normal&#xD;
      keratinocytes has identified two distinct groups of genetic expression based on clustering&#xD;
      patterns of a subgroup of genes. Clinical data was summarized for each group and overall,&#xD;
      patient segregation by gene expression profiling was a better predictor of outcome than&#xD;
      clinicopathological variables. Further analysis identified 375 genes that discriminate&#xD;
      between the genotypic subtypes of HNSCC. Overall, our preliminary data has shown that the&#xD;
      pattern of global gene expression in a HNSCC specimen can be used as a predictor of&#xD;
      prognosis. We isolated subsets of genes showing the greatest patterns of divergence in gene&#xD;
      expression. We have also identified 366 over-expressed and 246 underexpressed genes when&#xD;
      comparing primary tumor to normal surgical margins and have identified a similar number of&#xD;
      genes whose expression has changed when comparing primary tumor to lymph node metastasis.&#xD;
      Combining these data sets we have identified genes which consistently increase or decrease&#xD;
      expression during progression from normal tissue to primary tumor, and subsequently to&#xD;
      metastatic node. We have selected several candidate genes for subsequent analysis using HNSCC&#xD;
      tissue arrays. Through DNA microarray analysis and other techniques for looking at genetic&#xD;
      and molecular characteristics, a more detailed knowledge of the malignant transformation&#xD;
      process, and alterations with therapy, in these patients may be obtained. This study will&#xD;
      seek to perform comprehensive molecular and genetic profiling to improve biomarker&#xD;
      development in HNSCC and correlate this data with patient clinical data. Ultimately it is&#xD;
      hoped that tumor specific genetic abnormalities may be identified which could provide targets&#xD;
      for treatment strategies such as gene therapy, immunotherapy, or other interventions.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
      To evaluate gene expression patterns in human head and neck squamous cell carcinoma and&#xD;
      correlate this with treatment response, both surgical and non-surgical.&#xD;
&#xD;
      To identify a series of diagnostic markers in blood, urine and/or sputum for head and neck&#xD;
      squamous cell carcinoma and study the mechanism of action of these proteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>correlation of treatment response and prognosis (time to recurrence and survival) with genetic expression profile</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>identify a series of diagnostic markers for head and neck tumors and study the mechanism of action of these proteins</measure>
    <time_frame>variable</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Tumor specimens along with normal mucosa obtained at the time of surgery for biopsy or&#xD;
           resection of primary or recurrent tumors of the head and neck&#xD;
&#xD;
        2. blood, urine and sputum from patients participating in the tumor collection described&#xD;
           above&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tumors of the head and neck who ar ehaving diagnostic biopsy or surgical&#xD;
        resection of primary lesions or recurrences&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  actual or suspected malignant or non-malignant tumors of the head and neck&#xD;
&#xD;
          -  planned biopsy and/or resection, or availability of paraffin embedded or stored frozen&#xD;
             tumor tissue for non-genetic analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  insufficient tissue available for both standard diagnostic evaluation and study&#xD;
             specimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard V Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas J Ow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stelby Augustine, RN</last_name>
    <phone>718-920-7054</phone>
    <email>staugust@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard V Smith, MD</last_name>
    <phone>718-920-2991</phone>
    <email>rsmith@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stelby Augustine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stelby Augustine, RN</last_name>
      <phone>718-920-7054</phone>
      <email>staugust@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Richard V Smith, MD</last_name>
      <phone>718-920-2991</phone>
      <email>rsmith@montefore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Richard V Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Belbin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Prystowsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schiff Bradley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cohen Perry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ow Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehta Vikas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas F Schlecht, PhD, MSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Childs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madhur K Garg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Missak Haigentz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Rosenblatt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetic microarray</keyword>
  <keyword>head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

